PHARMAC

Pharmac – Te Pātaka Whaioranga is funding two new cancer treatments, for advanced breast cancer, and for blood cancer, which will improve health outcomes for hundreds of New Zealanders. Learn more: bit.ly/2024-02-15Cons…

Pharmac – Te Pātaka Whaioranga is funding two new cancer treatments, for advanced breast cancer, and for blood cancer, which will improve health outcomes for hundreds of New Zealanders. Learn more: bit.ly/2024-02-14-Not…

Last week our @Tuputoa_NZ interns presented their research projects and reflected on their time at Te Pātaka Whaioranga - Pharmac. Learn more about our interns: bit.ly/2024-02-12-Tup…

Pharmac – Te Pātaka Whaioranga is funding testosterone gel without restrictions as an additional testosterone treatment for anyone who needs it from 1 April 2024. Learn more: bit.ly/2024-02-08Noti…

Pharmac – Te Pātaka Whaioranga is seeking feedback on a joint proposal with Health New Zealand – Te Whatu Ora, to enable community pharmacies to give some of the funded childhood vaccines. Learn more: bit.ly/2024-01-14Cons…

Pharmac – Te Pātaka Whaioranga is funding more nutritional supplements for people with inherited metabolic diseases from 1 February 2024. Learn more: bit.ly/2024-01-11Fund…

Pharmac – Te Pātaka Whaioranga is seeking feedback on a proposal to fund two new treatments for advanced breast cancer and a type of blood cancer. The treatments are ribociclib (branded as Kisqali) and midostaurin (branded as Rydapt). Find out more bit.ly/2023-12-12cons…

Pharmac is widening access to COVID-19 antivirals to people who are vulnerable to severe infection from COVID-19, including those with disabilities and with one or more severe health conditions. Learn more: bit.ly/2023-09-20Covi…

Applications for the Hiwinui Heke Māori Pharmacy Scholarships are now open. Te Pātaka Whaioranaga in collaboration with Ngā Kaitiaki o Te Puna Rongoā o Aotearoa (Māori Pharmacists Association) is proud to offer this opportunity. Applications close 31 Oct. bit.ly/māoripharmacys…

The September edition of the Kauneke Update is out now. In this update we have a video from our Director of Strategy, Policy, and Performance talking about 30 years of Pharmac, the Pharmac Review, and our new Statement of Intent. View the update: bit.ly/2023-09-04Kaun…

Pharmac has confirmed it is widening access to two treatments today, emicizumab for the treatment of people with severe haemophilia A, and ocrelizumab for primary progressive multiple sclerosis. Learn more: bit.ly/2023-09-04Haem… bit.ly/2023-09-04Mult…

Pharmac is ensuring people with type 2 diabetes who use dulaglutide (branded as Trulicity) can continue to access this treatment. An alternative medicine is available and dispensing frequencies will be reduced from 1 September. Learn more: bit.ly/Dulaglutide202…

Te Pātaka Whaioranga - Pharmac is seeking bids from suppliers for two medicines, lenalidomide and pomalidomide, for use in the treatment of multiple myeloma. Learn more: bit.ly/RFP2023-08-24

Pharmac is transitioning to a trastuzumab biosimilar, Herzuma, from the currently funded brand, Herceptin. We are also widening access to locally advanced or metastatic HER2 positive gastric, gastro-oesophageal junction and oesophageal cancer. Learn more: bit.ly/Notification20…

Pharmac is interested to hear from suppliers who manufacture vaccines that protect against COVID-19 and are offering the opportunity to submit funding applications for future consideration. Learn more: bit.ly/CallForApplica…

Pharmac is planning to issue a competitive process for supply of oestradiol products. While we are considering this procurement process, we will continue to take every step we can to support the supply of currently funded treatments. Learn more: bit.ly/FPO2023-08-15

Pharmac is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type of brain cancer called glioma. This comes as lomustine is being discontinued. Learn more: bit.ly/Consultation20…

Pharmac has published the record of the March Rare Disorders Advisory Committee meeting, sharing details on a number of funding applications including those for spinal muscular atrophy (SMA). Learn more: bit.ly/2023-08-10rare…

There is a supply issue affecting vigabatrin tablets (Sabril). Sanofi, the supplier, has alerted Pharmac to a recall of this product at pharmacy level. We have arranged to make an alternative product available. Learn more about this issue on our website - pharmac.govt.nz/Sabril

Te Pātaka Whaioranga – Pharmac has confirmed supply agreements for a range of funded vaccines including those that protect against influenza and meningococcal disease. This follows a request for proposals (RFP) competitive process. Learn more: bit.ly/Notification20…